A unique case ofneonatal laryngeal neurofibromatosis is reported. The presenting symptoms are related to upper-airway obstruction. The available literature is discussed.
Neonatal Laryngeal Neurofibromatosis
Although neurofibroma of the larynx and pharynx has frequently been reported, the existence of diffuse laryngeal plexiform neurofibromatosis is uncommon and its presentation in the neonate very rare.
When airway obstruction and a gradually enlarging tumor in the neck are associated with the classic signs of Recklinghausen's diseasenamely, cutaneous tumors, cafe-au-lair spots, and a positive family history-a clinical diagnosis may be made. However, the local laryngeal symptoms may precede all the other features of the disease and make diagnosis difficult.
In the following report, the case of a female infant with diffuse plexiform neurofibromatosis in the paralaryngeal and parapharyngeal region associated with cafe-au-lait spots is described.
CASE REPORT
T.M., an infant Caucasian girl who was the second of monovular twins, was born at 31 weeks' gestation. From birth she was noted to have a small, round, mobile lump on the right side of her neck anterior to the sternocleidomastoid muscle (Figure 1 ). Because of respiratory distress syndrome and congestive cardiac failure, emergency endotracheal intubation and positive-pressure ventilation were required at one week of age. The neck lump gradually enlarged, became more diffuse and less mobile, and prevented permanent extubation. Removal of the endotracheal tube was associated with stridor, cyanosis, and a tachycardia. Direct laryngoscopy revealed a tumor in the right aryepiglottic fold, prolapsing medially over the glottic inlet, resulting in laryngeal distortion and rotation. The subglottis was normal. Reintubation was difficult because of the predominantly supraglottic position of the tumor. Surgical removal of the mass was attempted at age one month through a lateral horizontal neck incision. A diffuse soft-tissue tumor was found in the right parapharyngeal region, in direct continuity with the larynx (Figure 2 ).
The only recognizable neural structure was the hypoglossal nerve. The neoplasm had invaded the anterior and posterior bellies of the digastric and hyoid and could be removed en bloc submucosally from the larynx. Histopathologic examination (Figure 3 ) confirmed the diagnosis of Recklinghausen's disease. Postoperatively, the larynx returned to its normal position. The infant's general health deteriorated, however; there was tumor regrowth, and she died at the age of seven weeks. A family history revealed that her father had Recklinghausen's disease, although her twin sister shows no evidence of the disease. chronicled by Von Recklinghausen in 1882, the first description of the syndrome is attributed to Robert Smith (1849).1 It was not until 1930 that laryngeal involvement by neurofibromatosis was described by Colledge." Since then 19 additional cases have been added to the literature.:' Steichen et al. 4 have reported a similar case of neonatal laryngeal neurofibromatosis, but without any stigmata of Recklinghausen's disease.
DISCUSSION

Although diffuse neurofibromatosis was
Recklinghausen's disease is a disorder of neural-crest cells characterized clinically by overgrowths of neural and fibrous-tissue elements. It is inherited as an autosomal-dominant trait with variable penetrance. 5 A family history may be elicited in about 50 percent of cases, although this probably reflects a high incidence of spontaneous mutation." The pathologic devel-opment of the neural-crest cells may take one of several classic courses.f They may develop into solitary well-encapsulated neuroectodermal supportive-tissue tumors, which are life-threatening only on the basis of compromising anatomic location (e.g., acoustic nerve). A second group includes the less-well-encapsulated tumors arising from neurogenic tissue; this group includes the pheochromocytomas. A third developmental type isthe plexiform neurofibroma. This diffuse tumor is not encapsulated; its growth is centripetal, with proliferations of peripheral nerve elements. The pathologic tissue grows along nerve trunks and appears macroscopically as any array of tangled hypertrophied nerve filaments, often described rather aptly as having a "bag of worms" appearance.
In most clinical surveys of all pathologic types of the disease, the 'patients are frequently asymptomatic; only when tumors obstruct or compress vital organs do symptoms occur. Laryngeal neurofibromatosis is frequently associated with disease elsewhere in the neck and in the thorax. The most common signs and symptoms recorded in the 19 previously reported cases with laryngeal disease were hoarseness or voice change, dyspnea, dysphagia, and stridor. In most patients upper-airway obstruction was the primary indication for active treatment, which was surgical. Tracheostomy is the procedure of choice in laryngeal neurofibromatosis, as endotracheal intubation and simple upperrespiratory-tract infections may precipitate complete airway obstruction." The choice of Tegopen should take into consideration the fact that it has been shown to be effective only in the.treatment of infections caused by pneumococci, Group A Beta-hemolytic streptococci, and penicillin G-resistant and penicillin G-sensitive staphylococci. If the bacteriology report later indicates that the infection is due to an organism other than a penicillin G-resistant staphylococcus sensitive to cloxacillin sodium, the physician is advised to continue therapy with a drug other than cloxacillin sodium or any other penicillinase-resistant semisynthetic penicillin, Although in cases of discrete laryngeal neurofibromas endolaryngeal resection with microlaryngoscopy is feasible, an external approach is necessary for plexiform neurofibromas. These diffuse tumors, by reason of their anatomic relations, are not amenable to a single curative surgical procedure. However, partial excision when pressure symptoms prevail may gUOW time for resolution. There is little evidence to suggest that s~ch surgical intervention may result in malignant change. When such change is found, local tumor overgrowth more likely has produced anoxia within the neoplasm, resulting in degeneration and sarcomatous change. 0 62 Tegoperr (cloxacillin sodium)
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